Tumor-associated macrophages and CD8+T cells: dual players in the pathogenesis of HBV-related HCC

被引:2
|
作者
Khan, Muhammad Naveed [1 ,2 ]
Mao, Binli [3 ]
Hu, Juan [4 ]
Shi, Mengjia [1 ]
Wang, Shunyao [1 ]
Rehman, Adeel Ur [1 ]
Li, Xiaosong [1 ,2 ]
机构
[1] Chongqing Med Univ, Clin Mol Med Testing Ctr, Affiliated Hosp 1, Chongqing, Peoples R China
[2] Western Chongqing Collaborat Innovat Ctr Intellige, Chongqing, Peoples R China
[3] Chongqing Med Univ, Dept Blood Transfus, Affiliated Hosp 1, Chongqing, Peoples R China
[4] Suining Cent Hosp, Dept Clin Lab Med, Suining, Sichuan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatitis B virus; CD8+T cell; TAMs-like macrophage; HBV-related HCC; pathogenesis; immunology; CHRONIC HEPATITIS-B; T-CELL; HEPATOCELLULAR-CARCINOMA; DENDRITIC CELLS; IMMUNOSUPPRESSIVE MACROPHAGES; BLOCKADE; INFECTION; POLARIZATION; LYMPHOCYTES; EXHAUSTION;
D O I
10.3389/fimmu.2024.1472430
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
HBV infection is a key risk factor for the development and progression of hepatocellular carcinoma (HCC), a highly invasive tumor, and is characterized by its persistent immunosuppressive microenvironment. This review provides an in-depth analysis of HBV-related HCC and explores the interactions between neutrophils, natural killer cells, and dendritic cells, examining their roles in regulating tumor-associated macrophages and CD8+ T cells and shaping the tumor microenvironment. Two critical players in the immunosuppressive milieu of HBV-related HCC are CD8+ T cells and tumor-associated macrophages (TAMs). The study explores how TAMs, initially recruited to combat infection, transform, adopting a tumor-promoting phenotype, turning against the body, promoting tumor cell proliferation, suppressing anti-tumor immunity, and assisting in the spread of cancer. Meanwhile, CD8+ T cells, crucial for controlling HBV infection, become dysfunctional and exhausted in response to persistent chronic viral inflammation. The review then dissects how TAMs manipulate this immune response, further depleting CD8+ T cell functions through mechanisms like arginine deprivation and creating hypoxic environments that lead to exhaustion. Finally, it explores the challenges and promising therapeutic avenues that target TAMs and CD8+ T cells, either separately or in combination with antiviral therapy and personalized medicine approaches, offering hope for improved outcomes in HBV-related HCC.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Tumor-associated CD8+T cell tolerance induced by erythroid progenitor cells
    Fan, Xue
    Peng, Han
    Wang, Xuesong
    Sun, Yixin
    Dong, Yan
    Zhou, Jie
    Chen, Jianfang
    Huang, Shuo
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [2] Epigenetic regulation of HBV-specific tumor-infiltrating T cells in HBV-related HCC
    You, Maojun
    Gao, Yanan
    Fu, Junliang
    Xie, Runze
    Zhu, Zhenyu
    Hong, Zhixian
    Meng, Lingzhan
    Du, Shunda
    Liu, Junliang
    Wang, Fu-Sheng
    Yang, Pengyuan
    Chen, Liang
    HEPATOLOGY, 2023, 78 (03) : 943 - 958
  • [3] Induced Antigen Presentation by Tumor-Associated Macrophages Enhances Infiltration of CD8+T Cells with Low PD-1 Level
    Harada, Naozumi
    Muraoka, Daisuke
    Akiyoshi, Kazunari
    Shiku, Hiroshi
    CANCER SCIENCE, 2018, 109 : 300 - 300
  • [4] Lymph node and tumor-associated PD-L1+macrophages antagonize dendritic cell vaccines by suppressing CD8+T cells
    Sprooten, Jenny
    Vanmeerbeek, Isaure
    Datsi, Angeliki
    Govaerts, Jannes
    Naulaerts, Stefan
    Laureano, Raquel S.
    Borras, Daniel M.
    Calvet, Anna
    Malviya, Vanshika
    Kuballa, Marc
    Felsberg, Jorg
    Sabel, Michael C.
    Rapp, Marion
    Knobbe-Thomsen, Christiane
    Liu, Peng
    Zhao, Liwei
    Kepp, Oliver
    Boon, Louis
    Tejpar, Sabine
    Borst, Jannie
    Kroemer, Guido
    Schlenner, Susan
    De Vleeschouwer, Steven
    Sorg, Ruediger V.
    Garg, Abhishek D.
    CELL REPORTS MEDICINE, 2024, 5 (01)
  • [5] CXCR5+ CD8+ T cells could induce the death of tumor cells in HBV-related hepatocellular carcinoma
    Jin, Yun
    Lang, Cuicui
    Tang, Jianzhong
    Geng, Jiawei
    Song, Haihan K.
    Sun, Zhiwei
    Wang, Jinfeng
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2017, 53 : 42 - 48
  • [6] Tumor-infiltrating CD8+T cells combined with tumor-associated CD68+macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer
    Lu, Jun
    Xu, Yu
    Wu, Yuan
    Huang, Xiao-yan
    Xie, Jian-wei
    Wang, Jia-bin
    Lin, Jian-xian
    Li, Ping
    Zheng, Chao-hui
    Huang, Ai-min
    Huang, Chang-ming
    BMC CANCER, 2019, 19 (01)
  • [7] SUSTAINED OVEREXPRESSION OF PD-1 ON CD8+T CELLS WAS SIGNIFICANTLY ASSOCIATED WITH POOR PROGNOSIS IN PATIENTS WITH HBV-RELATED ACUTE-ON-CHRONIC LIVER FAILURE
    Liu, Xiaoyan
    Shi, Feng
    Tien, Po
    Wang, Fu-Sheng
    Wang, Huifen
    HEPATOLOGY, 2010, 52 (04) : 1085A - 1085A
  • [8] Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients
    Lulu Liu
    Junwei Liu
    Pan Li
    Jijun Luo
    Rui Qin
    Qiao Peng
    Bin Li
    Xuyong Wei
    Tian Wang
    Hongyu Shi
    Ming-Da Wang
    Chao Li
    Weijia Fang
    Wei Chen
    Xiao Xu
    Tian Yang
    Weiwei Yin
    Xun Zeng
    Journal of Experimental & Clinical Cancer Research, 42
  • [9] Targeting of SLAMF7 on human CD8+T cells to enhance responsiveness against tumor-associated antigens
    Sander, Jan-Erik
    Lingel, Holger
    Vogel, Katrin
    Arra, Aditya
    Han, Irina
    Fickenscher, Lisette
    Brunner-Weinzierl, Monika
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1123 - 1123
  • [10] Single-cell analysis reveals HBV-specific PD-1+CD8+ TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients
    Liu, Lulu
    Liu, Junwei
    Li, Pan
    Luo, Jijun
    Qin, Rui
    Peng, Qiao
    Li, Bin
    Wei, Xuyong
    Wang, Tian
    Shi, Hongyu
    Wang, Ming-Da
    Li, Chao
    Fang, Weijia
    Chen, Wei
    Xu, Xiao
    Yang, Tian
    Yin, Weiwei
    Zeng, Xun
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)